Takeda Pharmaceutical (TAK) Other Accumulated Expenses (2017 - 2026)

Takeda Pharmaceutical's Other Accumulated Expenses history runs 10 years deep, the most recent figure standing at $3.8 billion for Q1 2026.

• On a quarterly basis, Other Accumulated Expenses fell 3.72% year-over-year to $3.8 billion in Q1 2026; TTM through Mar 2026 was $3.8 billion, a 3.72% decrease from a year earlier, with the FY2026 full-year figure at $3.9 billion, changed 0.15% from the prior year.
• Other Accumulated Expenses improved to $3.8 billion in Q1 2026 per TAK's latest filing, from $3.7 billion in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $5.0 billion in Q1 2022 and bottomed at $3.3 billion in Q3 2024.
• The 5-year median for Other Accumulated Expenses is $4.0 billion (2023), against an average of $4.0 billion.
• Across the five-year window, Other Accumulated Expenses decreased 16.13% in 2024 and rose 2.51% in 2025, its largest moves.
• Year by year, Other Accumulated Expenses stood at $4.5 billion in 2022, then dropped by 12.6% to $4.0 billion in 2023, then fell by 5.98% to $3.7 billion in 2024, then retreated by 0.87% to $3.7 billion in 2025, then increased by 1.99% to $3.8 billion in 2026.
• Per Business Quant, the three latest TAK Other Accumulated Expenses figures stand at $3.8 billion (Q1 2026), $3.7 billion (Q4 2025), and $3.4 billion (Q3 2025).